Cargando…

Ascitic complement system in ovarian cancer

Ovarian cancer spreads intraperitoneally and forms fluid, whereby the diagnosis and therapy often become delayed. As the complement (C) system may provide a cytotoxic effector arm for both immunological surveillance and mAb-therapy, we have characterised the C system in the intraperitoneal ascitic f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bjørge, L, Hakulinen, J, Vintermyr, O K, Jarva, H, Jensen, T S, Iversen, O E, Meri, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361909/ https://www.ncbi.nlm.nih.gov/pubmed/15726105 http://dx.doi.org/10.1038/sj.bjc.6602334

Ejemplares similares

Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells
por: Junnikkala, S, et al.
Publicado: (2002)

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
por: Gavalas, N G, et al.
Publicado: (2012)

Ascites induces modulation of α6β1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma
por: Ahmed, N, et al.
Publicado: (2005)

Role of lymphangiogenesis in epithelial ovarian cancer
por: Sundar, S S, et al.
Publicado: (2006)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine
por: Golan, T, et al.
Publicado: (2014)

Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer
por: Uno, K, et al.
Publicado: (2007)

A distinct molecular profile associated with mucinous epithelial ovarian cancer
por: Heinzelmann-Schwarz, V A, et al.
Publicado: (2006)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas
por: Haldorsen, I S, et al.
Publicado: (2014)

Androgen-related expression of G-proteins in ovarian cancer
por: Sheach, L A, et al.
Publicado: (2009)

c-FOS suppresses ovarian cancer progression by changing adhesion
por: Oliveira-Ferrer, L, et al.
Publicado: (2014)

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
por: Burford, B, et al.
Publicado: (2013)

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
por: de Graeff, P, et al.
Publicado: (2008)

Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
por: Prang, N, et al.
Publicado: (2005)

BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
por: Lee, Y-K, et al.
Publicado: (2009)

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
por: Matsubara, J, et al.
Publicado: (2008)

Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer
por: Yagi, H, et al.
Publicado: (2005)

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
por: Bellone, S, et al.
Publicado: (2013)

Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival
por: Ino, K, et al.
Publicado: (2006)

Heparan sulphate synthetic and editing enzymes in ovarian cancer
por: Backen, A C, et al.
Publicado: (2007)

Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
por: Oikonomopoulou, K, et al.
Publicado: (2008)

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
por: Leffers, N, et al.
Publicado: (2010)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
por: O'Brien, P M, et al.
Publicado: (2008)

Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells
por: Yokota, N, et al.
Publicado: (2009)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer
por: Huh, J H, et al.
Publicado: (2013)

ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival
por: Brüning-Richardson, A, et al.
Publicado: (2011)

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
por: Hu, L, et al.
Publicado: (2010)

Prognostic role of CIP2A expression in serous ovarian cancer
por: Böckelman, C, et al.
Publicado: (2011)

Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer
por: Le Page, C, et al.
Publicado: (2006)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
por: Huhtinen, K, et al.
Publicado: (2009)

TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer
por: Liu, T, et al.
Publicado: (2013)

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer
por: Popple, A, et al.
Publicado: (2012)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies
por: de Graeff, P, et al.
Publicado: (2006)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer
por: van der Gun, B T F, et al.
Publicado: (2013)

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
por: Lee, S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_n9ckj7e80efdkn8dkkgcgfb83s